BFC Planning’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
BFC Planning's CRSP Position: Q3 2026 in Review
BFC Planning reduced its CRISPR Therapeutics (CRSP) stake by 35% in Q3 2026, selling an estimated $58.7K and leaving 2,018 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.
BFC Planning first reported a position in CRSP in Q3 2024 and has held it in 9 quarters since. The position peaked at $169K in Q2 2026. 423 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- BFC Planning held 2,018 shares of CRISPR Therapeutics worth $112K as of Q3 2026.
- BFC Planning sold 1,088 CRISPR Therapeutics shares in Q3 2026, an estimated $58.7K.
- CRISPR Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1183 holding.
- BFC Planning first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's CRISPR Therapeutics position peaked at $169K in Q2 2026.
- 423 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.